Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Open-Label Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Subjects With Myelofibrosis

Trial Profile

A Phase 2 Open-Label Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Subjects With Myelofibrosis

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Dec 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Navitoclax (Primary) ; Ruxolitinib
  • Indications Myelofibrosis
  • Focus Therapeutic Use
  • Sponsors AbbVie; AbbVie Germany
  • Most Recent Events

    • 26 Nov 2019 Planned End Date changed from 26 Sep 2028 to 20 Sep 2028.
    • 26 Nov 2019 Planned primary completion date changed from 20 Oct 2021 to 25 Mar 2020.
    • 06 Nov 2019 Results (data cut off: 1 May 2019) evaluating the combination of navitoclax with ruxolitinib in pts with MFreleased at the 61st Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top